Cancer
Cancer Ongoing 2021 North Shore NSW

KEYPAD

This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).

Trial overview

Disease
KEYPAD
Topic
KEYPAD
Description
Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial (ANZUP1601) KidnEY cancer Pembrolizumab And Denosumab.
Eligibility criteria
  • Kidney Cancer after progression on first line treatment
  • No prior treatment with immunotherapy 
Study details

The treatment is 3 weekly Pembrolizumab and Denosumab. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.

Location

North Shore NSW